Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy
Aharon Dick
, Joshua I. Rosenbloom
, Gilad Karavani
, Einat Gutman-Ido
, Naama Lessans
, Henry H. Chill
Division of Maternal-Fetal Medicine & Ultrasound
Institute of Clinical and Translational Sciences (ICTS)
Research output
:
Contribution to journal
›
Article
›
peer-review
26
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
During Pregnancy
100%
SARS-CoV-2 Vaccination
100%
Unvaccinated
100%
SARS-CoV-2 Vaccine
100%
Vaccine Booster
100%
Postpartum Hemorrhage
80%
Booster Dose
80%
Vaccination in Pregnancy
80%
Vaccination
60%
Obstetrical Outcomes
60%
Vaccination Dose
60%
Small-for-gestational-age Neonates
60%
Preterm Birth
40%
Retrospective Cohort Study
20%
Non-associated
20%
Pregnancy Outcome
20%
Fetus
20%
Adverse Outcomes
20%
With Woman
20%
No Adverse Effect
20%
Cesarean Delivery
20%
Neonatal Complications
20%
2-dose
20%
Exclusion Criteria
20%
Maternal Complications
20%
Sensitivity Analysis
20%
Preterm Labor
20%
Potential Confounders
20%
COVID-19
20%
Adverse Pregnancy Outcomes
20%
Umbilical Artery pH
20%
Gestational Diabetes Mellitus
20%
Hypertensive Disorders of Pregnancy
20%
Third Vaccination
20%
Multivariable Logistic Regression Model
20%
Symptomatic Disease
20%
Tertiary Medical Center
20%
Vaccinated Individuals
20%
Medicine and Dentistry
COVID-19 Vaccination
100%
Booster Dose
100%
COVID-19 Vaccine
100%
Lochia
80%
Premature Labor
60%
Neonate
60%
Small for Gestational Age
60%
Adverse Event
20%
Cesarean Section
20%
Adverse Outcome
20%
Retrospective Cohort Study
20%
Logistic Regression Analysis
20%
Gestational Diabetes
20%
Umbilical Artery
20%
COVID-19
20%
Diseases
20%
Nursing and Health Professions
Severe Acute Respiratory Syndrome
100%
Booster Dose
100%
Accident Prevention
100%
Postpartum Hemorrhage
66%
Neonate
50%
Premature Labor
50%
Small for Date Infant
50%
Cohort Analysis
16%
Logistic Regression Analysis
16%
Adverse Event
16%
Adverse Outcome
16%
Cesarean Section
16%
Pregnancy Diabetes Mellitus
16%
Arterial pH
16%
Diseases
16%
COVID-19
16%
Pharmacology, Toxicology and Pharmaceutical Science
COVID-19 Vaccine
100%
Vaccination
100%
SARS Coronavirus
45%
Postpartum Hemorrhage
36%
Premature Labor
27%
Small for Date Infant
27%
Cohort Study
9%
Adverse Event
9%
Adverse Outcome
9%
Pregnancy Diabetes Mellitus
9%
Diseases
9%